JP2000510836A - いかなる感染(特にhivを含むstd)、炎症、腫瘍、またはいかなる他の粘膜及び/または皮膚の疾患を予防及び/または治療するための方法及び処方 - Google Patents
いかなる感染(特にhivを含むstd)、炎症、腫瘍、またはいかなる他の粘膜及び/または皮膚の疾患を予防及び/または治療するための方法及び処方Info
- Publication number
- JP2000510836A JP2000510836A JP09540338A JP54033897A JP2000510836A JP 2000510836 A JP2000510836 A JP 2000510836A JP 09540338 A JP09540338 A JP 09540338A JP 54033897 A JP54033897 A JP 54033897A JP 2000510836 A JP2000510836 A JP 2000510836A
- Authority
- JP
- Japan
- Prior art keywords
- gel
- gel formulation
- liposomes
- poloxamer
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/801—Drug
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/912—Cancer cell repair
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.広がって患者の皮膚または粘膜上に保護層を形成することが可能なゲル構成 成分を含む、患者における伝播可能な病原体によって引き起こされる疾患を予防 するためのゲル処方で、上記ゲル処方は上記患者の皮膚または粘膜の点で、感染 環境から非感染環境へ上記病原体の透過を予防することが可能であるゲル処方。 2.上記ゲル構成成分が熱可逆的である請求項1記載のゲル処方。 3.該熱可逆的ゲル構成成分がポロキサマーである請求項2記載のゲル処方。 4.該ポロキサマーがポロキサマー407である請求項3記載のゲル処方。 5.ポロキサマー407が約10から50%(w/w)の濃度で存在する請求項4記載のゲル処 方。 6.ポロキサマー407が約18%(w/w)の濃度で存在する請求項5記載のゲル処方。 7.ポロキサマー407が約19.5%(w/w)の濃度で存在する請求項5記載のゲル処方。 8.さらに殺菌薬、抗ウイルス試薬、化学療法試薬、抗炎症試薬、抗毒素、免疫 療法試薬、抗ヒスタミン試薬、殺精子薬、患者の組織構成成分に対するまたは上 記病原体に対するワクチンを、それそれ単独または組み合わせて含む請求項1か ら7のいずれか一項記載のゲル処方。 9.該殺菌薬または殺精子薬が、硫酸デキストリン、サキナビル、インジナビル 、リトナビル、AZT、ddC、ddl、3TC、ホスカネット、リバビリン、アシクロビル 、ガンシクロビル、ノンオキシノール−9,塩化ベンザルコニウム、及びメンフ ェゴールより成る群から選択される請求項8記載のゲル処方。 10.少なくとも上記殺菌薬または試薬の一部がリポソーム、ナノ粒子またはシク ロデキストリンに封入されている請求項8または9記載のゲル処方。 11.少なくとも上記殺菌薬または試薬の一部がリポソームに封入されている請求 項10記載のゲル処方。 12.該リポソームが、10:1から1:1の間のモル比でジアシルホスファチジルコリ ン及びジアシルホスファチジルグリセロールの混合物を含む請求項11記載のゲ ル処方で、該アシル鎖が飽和または不飽和のいずれかであり、長さにおいて14か ら18炭素原子を持つゲル処方。 13.該リポソームがさらに、ジアシルホスファチジルエタノールアミンのポリエ チレングリコール誘導体を含む請求項12記載のゲル処方。 14.該リポソームがジアシルホスファチジルコリン:ジセチルホスフェート:コ レステロールの混合物より成る請求項11記載のゲル処方で、該アシル鎖が飽和 または不飽和のいずれかであり、長さにおいて14から18炭素原子を持つゲル処方 。 15.該リポソームがさらに、ジアシルホスファチジルエタノールアミンのポリエ チレングリコール誘導体を含む請求項14記載のゲル処方。 16.該リポソームが、10:3のモル比でジステアロイルホスファチジルコリン:ジ ステアロイルホスファチジルグリセロールより成り、該封入された薬剤がddlで ある請求項12記載のゲル処方。 17.該リポソームが、10:3:1.45のモル比でジステアロイルホスファチジルコリ ン:ジステアロイルホスファチジルグリセロール:ジステアロイルホスファチジ ルエタノールアミン−ポリエチレングリコールより成り、該封入された薬剤がdd lで ある請求項13記載のゲル処方。 18.該リポソームが、4:1:5のモル比でジパルミトイルホスファチジルコリン: ジセチルホスフェート:コレステロールより成り、該封入された薬剤がddCであ る請求項14記載のゲル処方。 19.該リポソームが、10:3のモル比でジパルミトイルホスファチジルコリン:ジ パルミトイルホスファチジルグリセロールより成り、該封入された薬剤がホスカ ネットである請求項12記載のゲル処方。 20.該リポソームが、簡便な、立体的に安定なリポソーム、イムノリポソーム、 pH感受性リポソーム、熱感受性リポソームまたはターゲット感受性リポソームで ある請求項11記載のゲル処方。 21.膣、子宮頸部、肛門直腸、目、口、鼻粘膜、または皮膚を含む異なるタイプ の粘膜に適用され、あるいは眼的使用のために目内に注入される請求項1から2 0のいずれか一項記載のゲル処方。 22.粘膜または皮膚を通した病原体の伝播を予防する方法で、上記病原体による 感染に感受性の患者の皮膚または粘膜に対して、請求項1から21のいずれか一 項に定義されるゲル処方を適用する段階を含む方法。 23.皮膚または粘膜に影響する疾患を治療し、一方でそれを通した病原体の伝播 を避ける方法で、上記治療の必要のある患者の皮膚または粘膜に対して、請求項 7から20のいずれか一項に定義されるゲル処方を適用する段階を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1710696P | 1996-05-09 | 1996-05-09 | |
US60/017,106 | 1996-05-09 | ||
PCT/CA1997/000319 WO1997042962A1 (en) | 1996-05-09 | 1997-05-09 | Formulation for use in the prevention of pathogen induced diseases including hiv and hsv |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000510836A true JP2000510836A (ja) | 2000-08-22 |
Family
ID=21780760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09540338A Pending JP2000510836A (ja) | 1996-05-09 | 1997-05-09 | いかなる感染(特にhivを含むstd)、炎症、腫瘍、またはいかなる他の粘膜及び/または皮膚の疾患を予防及び/または治療するための方法及び処方 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6068851A (ja) |
EP (1) | EP0930886B1 (ja) |
JP (1) | JP2000510836A (ja) |
KR (1) | KR20000010834A (ja) |
CN (1) | CN1177594C (ja) |
AP (1) | AP1406A (ja) |
AT (1) | ATE269711T1 (ja) |
AU (1) | AU723081B2 (ja) |
BR (1) | BR9709228A (ja) |
CA (1) | CA2258811C (ja) |
DE (1) | DE69729646T2 (ja) |
HK (1) | HK1019560A1 (ja) |
IL (1) | IL126804A0 (ja) |
NO (1) | NO985148L (ja) |
NZ (1) | NZ332578A (ja) |
OA (1) | OA11096A (ja) |
WO (1) | WO1997042962A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006111585A (ja) * | 2004-10-15 | 2006-04-27 | Mebiol Kk | 徐放性組成物およびその徐放方法 |
WO2006054589A1 (ja) * | 2004-11-18 | 2006-05-26 | Terumo Kabushiki Kaisha | 医薬組成物、製剤および組み合わせ製剤 |
JP2007533755A (ja) * | 2004-04-20 | 2007-11-22 | ザ ユニヴァーシティ オヴ シカゴ | 高分子量peg様化合物を含む治療薬送達システム |
JP2015515992A (ja) * | 2012-05-04 | 2015-06-04 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2773994B1 (fr) * | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
US6482805B2 (en) * | 1998-03-25 | 2002-11-19 | Parker Hughes Institute | AZT derivatives exhibiting spermicidal and anti-viral activity |
US6191120B1 (en) * | 1998-03-25 | 2001-02-20 | Wayne Hughes Institute | Spermicidally active 5-halo-6-alkoxy-5,6-dihydro-2′,3′-dideoxy-uridines and their pharamaceutical compositions |
KR20010042875A (ko) * | 1998-04-21 | 2001-05-25 | 엥펙시오 르쉐르쉬 엥꼬르뽀라시옹 | 폴록사머 및 추가의 살미생물제를 함유하는 국소용 조성물및 어플리케이터 |
US6030957A (en) | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
US6541020B1 (en) * | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
AU4343101A (en) * | 2000-03-07 | 2001-09-17 | Rush Presbyterian St Luke | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
US6835717B2 (en) * | 2000-03-08 | 2004-12-28 | The Johns Hopkins University School Of Medicine | β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
AU2001270147A1 (en) * | 2000-06-23 | 2002-01-08 | Merck & Co., Inc. | Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
US7465295B2 (en) | 2000-10-20 | 2008-12-16 | Bergeron Michel G | Applicator for the delivery of topical formulations into mucosal cavities |
AU2003205227A1 (en) * | 2002-01-18 | 2003-09-02 | Emory University | Phthalocyanine and porphyrazine pharmaceutical compositions |
CN1314452C (zh) * | 2002-04-22 | 2007-05-09 | 沈阳药科大学 | 具有适宜相转变温度的眼用原位凝胶制剂 |
US7151091B2 (en) * | 2002-09-20 | 2006-12-19 | The Johns Hopkins University | Compositions and methods for preventing infection |
US20130085146A1 (en) * | 2003-01-14 | 2013-04-04 | Rodney J.Y. Ho | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
US20050014719A1 (en) * | 2003-06-24 | 2005-01-20 | Khan Adil A. | Method of controlling viral outbreak |
US20050095283A1 (en) * | 2003-09-16 | 2005-05-05 | Aphios Corporation | Compositions and methods for topically treating diseases |
WO2005097210A1 (en) * | 2004-03-26 | 2005-10-20 | The University Of Utah Research Foundation | Bioresponsive polymer system for delivery of microbicides |
US20060127459A1 (en) * | 2004-12-15 | 2006-06-15 | Lei Huang | Urogenital infection inhibition |
US20080078408A1 (en) * | 2005-04-18 | 2008-04-03 | Park Benjamin W | Urethral condoms and liquid female condoms |
WO2006112632A1 (en) * | 2005-04-18 | 2006-10-26 | Benjamin Won Park | Urethral condoms and liquid femidoms |
KR100775315B1 (ko) | 2005-08-03 | 2007-11-08 | 벤자민 원 박 | 성병과 에이즈예방용 윤활젤 조성물 |
US20070134747A1 (en) * | 2005-12-14 | 2007-06-14 | Kimberly-Clark Worldwide, Inc. | Detection of secreted lipase proteins from Candida species |
US7745158B2 (en) * | 2005-12-14 | 2010-06-29 | Kimberly-Clark Worldwide, Inc. | Detection of secreted aspartyl proteases from Candida species |
BRPI0811071A2 (pt) * | 2007-05-04 | 2014-09-23 | Procter & Gamble | Produtos, composições microbicidas, e métodos de uso |
EP2219608B1 (en) * | 2007-12-03 | 2014-03-19 | Trilogic Pharma Llc | Self solidifying bioerodible barrier implant |
US20110256213A1 (en) * | 2008-10-15 | 2011-10-20 | The Board Of Trustees Of The University Of Illinois | Phospholipid micellar and liposomal compositions and uses thereof |
DE102009034771B4 (de) * | 2009-07-25 | 2011-09-01 | Martin Schmitt | Hautschutzmittel |
DK177532B1 (en) * | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
WO2011084610A1 (en) * | 2009-12-16 | 2011-07-14 | Children Medical Center Corporation | Liposomes for preventing the spread of hiv |
WO2011153334A2 (en) * | 2010-06-04 | 2011-12-08 | Trilogic Pharma Llc | Bioadhesive compositions for epithelial drug delivery |
US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
EP3013368A1 (en) | 2013-06-25 | 2016-05-04 | Mission Pharmacal Company | Novel formulations for the treatment of vaginal disorders |
AU2016211696B2 (en) | 2015-01-27 | 2018-05-10 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
EP3484485A1 (en) * | 2016-07-12 | 2019-05-22 | Centre National De La Recherche Scientifique | Compositions useful for mucosal healing |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5151438A (en) * | 1989-05-23 | 1992-09-29 | Abbott Laboratories | Retroviral protease inhibiting compounds |
IT1240354B (it) * | 1990-03-30 | 1993-12-07 | Poli Ind Chimica Spa | Formulazioni liposomiali di farmaci antimicotici,antibatterici e/o antantiflogistici per applicazione locale e vaginale |
US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
IT1250748B (it) * | 1991-08-02 | 1995-04-21 | Poli Ind Chimica Spa | Formulazioni utili per il trattamento della secchezza vaginale |
IT1255460B (it) * | 1992-07-28 | 1995-11-02 | Poli Ind Chimica Spa | Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive |
EP0789565A4 (en) * | 1993-10-15 | 1999-03-24 | Jess G Thoene | PREVENTION OF HIV INFECTION |
-
1997
- 1997-05-09 CA CA002258811A patent/CA2258811C/en not_active Expired - Lifetime
- 1997-05-09 US US09/051,300 patent/US6068851A/en not_active Expired - Lifetime
- 1997-05-09 NZ NZ332578A patent/NZ332578A/en unknown
- 1997-05-09 EP EP97917971A patent/EP0930886B1/en not_active Expired - Lifetime
- 1997-05-09 AU AU26299/97A patent/AU723081B2/en not_active Ceased
- 1997-05-09 DE DE69729646T patent/DE69729646T2/de not_active Expired - Lifetime
- 1997-05-09 WO PCT/CA1997/000319 patent/WO1997042962A1/en not_active Application Discontinuation
- 1997-05-09 CN CNB97194489XA patent/CN1177594C/zh not_active Expired - Lifetime
- 1997-05-09 JP JP09540338A patent/JP2000510836A/ja active Pending
- 1997-05-09 AT AT97917971T patent/ATE269711T1/de not_active IP Right Cessation
- 1997-05-09 AP APAP/P/1998/001382A patent/AP1406A/en active
- 1997-05-09 KR KR1019980708975A patent/KR20000010834A/ko not_active Application Discontinuation
- 1997-05-09 IL IL12680497A patent/IL126804A0/xx unknown
- 1997-05-09 BR BR9709228A patent/BR9709228A/pt not_active Application Discontinuation
-
1998
- 1998-11-04 NO NO985148A patent/NO985148L/no not_active Application Discontinuation
- 1998-11-09 OA OA9800219A patent/OA11096A/en unknown
-
1999
- 1999-10-27 HK HK99014789A patent/HK1019560A1/xx not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007533755A (ja) * | 2004-04-20 | 2007-11-22 | ザ ユニヴァーシティ オヴ シカゴ | 高分子量peg様化合物を含む治療薬送達システム |
JP2006111585A (ja) * | 2004-10-15 | 2006-04-27 | Mebiol Kk | 徐放性組成物およびその徐放方法 |
WO2006054589A1 (ja) * | 2004-11-18 | 2006-05-26 | Terumo Kabushiki Kaisha | 医薬組成物、製剤および組み合わせ製剤 |
JPWO2006054589A1 (ja) * | 2004-11-18 | 2008-05-29 | テルモ株式会社 | 医薬組成物、製剤および組み合わせ製剤 |
JP5110880B2 (ja) * | 2004-11-18 | 2012-12-26 | テルモ株式会社 | 医薬組成物、製剤および組み合わせ製剤 |
JP2015515992A (ja) * | 2012-05-04 | 2015-06-04 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
Also Published As
Publication number | Publication date |
---|---|
NO985148L (no) | 1999-01-08 |
AP9801382A0 (en) | 1998-12-31 |
CN1218403A (zh) | 1999-06-02 |
BR9709228A (pt) | 1999-08-10 |
ATE269711T1 (de) | 2004-07-15 |
DE69729646T2 (de) | 2005-07-07 |
KR20000010834A (ko) | 2000-02-25 |
NO985148D0 (no) | 1998-11-04 |
IL126804A0 (en) | 1999-08-17 |
WO1997042962A1 (en) | 1997-11-20 |
DE69729646D1 (de) | 2004-07-29 |
EP0930886A1 (en) | 1999-07-28 |
AU2629997A (en) | 1997-12-05 |
AP1406A (en) | 2005-05-04 |
CA2258811C (en) | 2003-11-25 |
HK1019560A1 (en) | 2000-02-18 |
EP0930886B1 (en) | 2004-06-23 |
OA11096A (en) | 2003-03-13 |
US6068851A (en) | 2000-05-30 |
AU723081B2 (en) | 2000-08-17 |
NZ332578A (en) | 2000-06-23 |
CA2258811A1 (en) | 1997-11-20 |
CN1177594C (zh) | 2004-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000510836A (ja) | いかなる感染(特にhivを含むstd)、炎症、腫瘍、またはいかなる他の粘膜及び/または皮膚の疾患を予防及び/または治療するための方法及び処方 | |
JP4665075B2 (ja) | 粘膜または皮膚を冒す疾病の防止または治療のための、または妊娠の防止のための製剤、および、粘膜腔内に局所用製剤を到達させるためのアプリケーター | |
US9737498B2 (en) | Method for treating an inflammation or lesion caused by a virus | |
WO1995028165A1 (en) | Coated products with potent anti-hiv and antimicrobial properties | |
JP2002515410A (ja) | 広域スペクトルの殺菌用及び殺精子用の組成物、装置、及び方法 | |
EP1996209A1 (en) | Contraceptive composition | |
Thakur et al. | Current state of nanomedicines in the treatment of topical infectious disorders | |
EP1858531A1 (en) | Use of copper silicate for the control of herpes infections | |
AU2002251933B2 (en) | Virucidal compositions | |
AU2002251933A1 (en) | Virucidal compositions | |
BRPI0620907A2 (pt) | composição farmacêutica, sistema de distribuição de droga vaginal e uso da composição farmacêutica | |
JP2559735B2 (ja) | 抗ー微生物組成物 | |
JP2006518719A (ja) | ヘルペスの治療のためのpvp−ヨウ素リポソームの使用 | |
RU2161961C1 (ru) | Лекарственный препарат | |
EA022283B1 (ru) | Лекарственный препарат, содержащий бензилдиметил[3-(миристоиламино)пропил]аммония хлорид | |
CA2257001A1 (en) | Method and formulations for prevention of infection of mucosae and/or skin and development of a vaginal/ano-rectal applicator for the delivery of topical formulations | |
PL237937B1 (pl) | Preparat farmaceutyczny do leczenia zakażenia wirusem herpes simplex | |
AU2006225096A1 (en) | Use of Copper Silicate for the Control of Herpes Infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080513 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080701 |